MatTek Human 3D Tissue (인공피부)

The EpiIntestinal™ (MatTek)

A human 3D in vitro small intestinal tissue model with epithelial polarity to evaluate toxicity, metabolism, drug absorption and compound efficacy. MatTek’s novel innovation to help redefine gastrointestinal preclinical testing.

제품 상세정보

EpiIntestinal™

MatTek’s 3D tissue model of the human small intestine is advancing in vitro GI research worldwide. Allowing for physiological exposures and human-relevant endpoints, EpiIntestinal is being incorporated into pharmaceutical development and microbiome discovery programs across the globe.

  • Epithelial Polarity
  • Highly Differentiated, Physiologically Relevant
  • Multiple Donors Available
  • Delivered Ready-to-use & Easy-to-use

Request the EpiIntestinal Data Sheet



 

 

 


The EpiIntestinal tissue model (SMI-100) offers numerous advantages versus currently available preclinical testing models such as Caco-2. The human cell-based 3D model incorporates enterocytes, paneth cell, M cells, tuft cells and intestinal stem cells into a highly differentiated,  polarized epithelium. The EpiIntestinalFT tissue (SMI-100-FT) includes an underlying lamina propria containing normal human intestinal fibroblasts and is useful to study inflammation, wound repair, innate immune responses, and fibrosis. Both tissues are cultured at the air-liquid interface (ALI) to allow physiological (luminal) exposure conditions. EpiIntestinal recapitulates  many aspects of normal intestinal function including  barrier, metabolism, inflammatory and toxicity responses, similar to native human intestinal tissue. 


 
Important features of EpiIntestinal include the presence of functional tight junctions and brush borders at the apical tissue surface.  In vivo, brush borders are in direct contact with luminal contents and include at least 22 metabolic enzymes and 19 drug transporters.  EpiIntestinal tight junctions and brush borders closely mimic human structure and physiology. 


 

 

Tissue:

Kit: SMI-100 and SMI-100-FT EpiIntestinal kits consist of 24 individual tissues. SMI-196 or SMI-196-FT EpiIntestinal kits consist of 96 tissues in a high throughput screening plate. Each kit  contains tissues, culture medium to support experiments for 24 hours, and plasticware.  Please contact MatTek for specific kit contents.

Formats:

  • SMI-100 and SMI-100-FT:  Individual tissues cultured in cell culture inserts.Dimensions:  9 mm tissue diameter (surface area= 0.6 cm2 ), underlying microporous membrane pore size =  0.4 μm
  • SMI-196 and SMI-196-FT:  Tissues grown in 96-well high throughput screening plate.  Dimensions:  0.19 cm tissue diameter (surface area= 0.11 cm2).  Underlying microporous membrane pore size =0.4 μm

Culture: Air-liquid interface

Lot numbers: Tissue lots produced each week are assigned a specific lot number. A letter of the alphabet is appended to the end of the lot number to differentiate between individual sets of 24 tissues within a given production lot of tissues. All tissue kits within a production lot are identical in regards to cells, medium, handling, culture conditions, etc.

Shipment: At 4°C on medium-supplemented, agarose gels

Shipment day: Every Monday

Delivery: Tuesday morning via FedEx priority service (US). Outside US: Tuesday-Wednesday depending on location.

Shelf life: Including time in transit, tissues may be stored at 4°C for up to 2 days prior to use. However, the best reproducibility will be obtained if tissues are used consistently on the same day, e.g. Tuesday afternoon or following overnight storage at 4°C (Wednesday morning).

Length of experiments: Tissue cultures can be continued for ONE (1) MONTH or more with good retention of normal morphology. Tissues must be fed every other day with 5.0 ml of maintenance medium (SMI-100-MM). Cell culture inserts are placed atop washers (EPI-WSHR) or culture stands (MEL-STND) in 6-well plates to allow use of 5.0 ml.

Cells:

Type: Primary human small intestinal epithelial cells (HSIE)

Genetic make-up: Single donor

Derived from: Healthy adult donor

Alternatives: Alternate donors available upon request

Screened for: HIV, Hepatitis-B, Hepatitis-C, mycoplasma

Medium:

Base medium: Dulbecco’s Modified Eagle’s Medium (DMEM)

Growth factors/hormones: Epidermal growth factor and other proprietary factors

Antibiotics: Gentamicin 5 µg/ml

Anti-fungal agent: Amphotericin B 0.25 µg/ml

pH Indicator: Phenol red

Other additives: Proprietary

Alternatives: Phenol red-free, antibiotic-free, anti-fungal-free medium and tissues are available. Agents are removed at least 3 days prior to shipment.

Quality Control and Sterility:

Visual inspection: All tissues are visually inspected and if physical imperfections are noted, tissues are rejected for shipment

Sterility: All media used throughout the production process is checked for sterility. Maintenance medium is incubated with and without antibiotics for 1 week and checked for sterility. The agarose gel from the 24-well plate used for shipping is also incubated for 1 week and checked for any sign of contamination

Screening for pathogens: All cells are screened and are negative for HIV, hepatitis B and hepatitis C using PCR. However, no known test method can offer complete assurance that the cells are pathogen free. Thus, these products and all human derived products should be handled at BSL-2 levels (biosafety level 2) or higher as recommended in the CDC-NIH manual, “Biosafety in microbiological and biomedical laboratories,” 1998. For further assistance, please contact your site Safety Officer or MatTek technical service

Notification of lot failure: If a tissue lot fails QC or sterility testing, the customer will be notified and the tissues will be replaced without charge. Because our QC and sterility testing is done post-shipment, notification will be made as soon as possible (Under normal circumstances, ET-50 failures will be notified by Thursday 5 p.m.; sterility failures will be notified within 8 days of shipment)



 

The EpiIntestinal 3D human tissue model is routinely utilized for screening pharmaceuticals for a range of endpoints including GI toxicity and inflammation, drug metabolism, drug permeation, fibrosis, and intestinal infection. Straightforward protocols and the evaluation of early molecular and cellular endpoints often allow scientists to acquire data in days, not weeks or months.

EpiIntestinal Use Protocol

EpiIntestinalFT Use Protocol

GI Toxicity

Use EpiIntestinal for a highly predictive assay to evaluate GI toxicity of pharmaceuticals.

EpiIntestinal (SMI-100) Transepithelial Electrical Resistance (TEER) Protocol

GI Toxicity Reference Paper

Inflammation and Fibrosis

Utilize EpiIntestinal’s highly controlled in vitro culture conditions to study intestinal inflammation, wound repair, and fibrosis, and assess therapeutic effects.

Intestinal Inflammation Reference Paper

Drug Delivery & Metabolism

Utilize EpiIntestinal for highly predictive and human-relevant drug delivery.  Assess API bioavailability (influx) and efflux transport, drug metabolism, and drug-drug interactions.  EpiIntestinal can be co-cultured with other physiological systems (e.g. liver cells) in microfluidic systems to examine the effect of drug metabolites on GI toxicity or to predict drug permeation/absorption via the “luminal” side of the tissue.

EpiIntestinal Drug Permeation Protocol

Intestinal Drug Delivery Reference Paper

Wound Repair/Epithelial Restitution

Use EpiIntestinalFT to better understand mechanisms of wound healing in the gut and to evaluate therapeutic effects.

Intestinal Restitution Reference Paper

Intestinal Infection

Utilize EpiIntestinal to study GI tract infection, host-pathogen interactions, and innate immune responses.

Browse our reference library to learn more about how researchers have used our EpiIntestinal tissue in these areas of study.

Human relevant data in a high-throughput in vitro tissue model.

Learn how EpiIntestinal is breaking new ground in preclinical testing.



Human Relevance


 in vitro Human Intestinal Tissue Model To Assess and Predict Drug Induced-GI Damage